Solid Tumors Clinical Trials in Philadelphia, Pennsylvania
29 recruitingPhiladelphia, Pennsylvania
Showing 1–20 of 29 trials
Recruiting
Phase 1
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 1Phase 2
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1Phase 2
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
Solid Tumors
Incyte Corporation604 enrolled42 locationsNCT05238922
Recruiting
Phase 1Phase 2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Advanced Solid Tumors
Regeneron Pharmaceuticals933 enrolled57 locationsNCT04626635
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 1Phase 2
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.27 enrolled4 locationsNCT07192432
Recruiting
Phase 1Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
SNV4818 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Pikavation Therapeutics, Inc.320 enrolled12 locationsNCT06736704
Recruiting
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
Incyte Corporation710 enrolled34 locationsNCT06179160
Recruiting
Phase 1Phase 2
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Lung CancersLocally AdvancedSolid Tumor Cancer+2 more
Avenzo Therapeutics, Inc.430 enrolled16 locationsNCT07038343
Recruiting
Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled27 locationsNCT07094113
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Solid TumorsAdvanced Solid TumorsMetastatic Solid Tumors
Incyte Corporation408 enrolled36 locationsNCT05836324
Recruiting
Phase 1Phase 2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
LymphomaMetastatic Solid TumorsLocally Advanced Solid Tumors+1 more
Turning Point Therapeutics, Inc.75 enrolled68 locationsNCT04094610
Recruiting
Phase 1Phase 2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
ORIC Pharmaceuticals350 enrolled42 locationsNCT05315700
Recruiting
Phase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Mesothelin-Expressing TumorsEpithelial Ovarian CancerLung Adenocarcinoma Metastatic+7 more
Context Therapeutics Inc.70 enrolled8 locationsNCT06756035
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316